Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00914667 · ClinicalTrials.gov registry record · Phase 1
The Effect Of Fesoterodine On Pharmacokinetics And Pharmacodynamics Of Warfarin In Healthy Subjects
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
NCT00914667 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 14 participants.
The verdict
NCT00914667, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
This is an open-label, randomized, two-way crossover study to evaluate the steady-state effect of fesoterodine (8 mg QD) on the pharmacodynamics and pharmacokinetics of a single supratherapeutic dose of warfarin (25 mg) in healthy subjects.
Interventions
- DRUG warfarin
- DRUG Warfarin plus Fesoterodine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2009-07 |
| Est. Completion | 2009-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00914667
The ClinicalTrials.gov registry entry for NCT00914667 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which warfarin is the first listed.
NCT00914667 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00914667 about?
NCT00914667 is a clinical study titled "The Effect Of Fesoterodine On Pharmacokinetics And Pharmacodynamics Of Warfarin In Healthy Subjects". This is an open-label, randomized, two-way crossover study to evaluate the steady-state effect of fesoterodine (8 mg QD) on the pharmacodynamics and pharmacokinetics of a single supratherapeutic dose of warfarin (25 mg) in healthy subjects.
What is the current status of trial NCT00914667?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2009-07. Estimated completion is 2009-08.
What interventions are being tested in trial NCT00914667?
The interventions under investigation include: warfarin (DRUG), Warfarin plus Fesoterodine (DRUG).
Who is sponsoring clinical trial NCT00914667?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.